How Much Does Belsomra (Suvorexant) Cost in Ohio in 2026?

Ohio Retail Pharmacy Prices for Belsomra

The gap between Belsomra's list price and what Ohio patients actually pay at the counter is significant. Merck's wholesale acquisition cost (WAC) remains $340 per month for a 30-count supply of either the 10 mg or 20 mg tablet. Ohio retail pharmacies, however, report an average cash price near $85 per month in 2026 after discount card and pharmacy benefit manager (PBM) negotiations are factored in.

Prices vary by pharmacy chain and location within the state. Independent pharmacies in rural Ohio counties may price Belsomra differently than CVS or Walgreens locations in Columbus, Cleveland, or Cincinnati. Always compare prices across at least three pharmacies before filling. GoodRx-type discount platforms often show per-tablet pricing that can reduce out-of-pocket expense below the $85 average.

Suvorexant was the first dual orexin receptor antagonist (DORA) approved by the FDA in August 2014. The key trial by Herring et al. (Lancet Neurology, 2014; N=3,291) demonstrated that suvorexant improved subjective total sleep time by approximately 20 minutes over placebo at four weeks, with sustained efficacy at three months. That clinical profile supports continued prescriber interest, but cost remains the primary barrier for many Ohio patients without adequate prescription coverage.

Ohio Medicaid and Belsomra Coverage

Ohio Medicaid does not cover Belsomra for primary insomnia. The Ohio Department of Medicaid formulary restricts suvorexant to a narrow indication tied to type 2 diabetes comorbidity, a classification that effectively excludes most insomnia-only patients.

This restriction reflects a broader pattern among state Medicaid programs. Because generic alternatives like zolpidem (Ambien) and eszopiclone (Lunesta) cost a fraction of Belsomra's price, Medicaid preferred drug lists tend to favor older sedative-hypnotics. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline lists suvorexant as a recommended option for sleep-onset and sleep-maintenance insomnia, but payer formularies weigh cost-effectiveness alongside clinical evidence.

Ohio Medicaid enrollees who need a DORA specifically (for example, patients with contraindications to benzodiazepine receptor agonists or a history of complex sleep behaviors on zolpidem) can request a prior authorization. The process requires the prescribing physician to document two or more failed generic alternatives and a clinical rationale explaining why suvorexant is medically necessary. Approval rates for these requests vary, and denials can be appealed through the Ohio Medicaid unified grievance system.

For Ohio Medicaid patients denied coverage, the Merck Patient Assistance Program may provide Belsomra at no cost to qualifying individuals with household income below 400% of the federal poverty level.

Commercial Insurance Coverage in Ohio

Most major commercial insurers operating in Ohio place Belsomra on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. This means copays typically range from $40 to $75 per month after deductible, depending on the specific plan.

Anthem Blue Cross and Blue Shield of Ohio, the state's largest commercial insurer, covers Belsomra on its Tier 3 list with a standard prior authorization requirement. UnitedHealthcare plans sold through the Ohio marketplace generally classify suvorexant as Tier 3 with step therapy, meaning patients must try and fail a generic sleep aid before approval. Medical Mutual of Ohio and SummaCare follow similar patterns.

The Endocrine Society's 2017 clinical practice guideline on pharmacologic management of insomnia notes that DORA-class medications offer a different mechanism of action compared to GABA-modulating drugs, which may justify their use after first-line failure. Prescribers in Ohio can cite this guideline when completing prior authorization forms.

Self-funded employer plans (ERISA plans) are not bound by Ohio state mandates and may have different formulary rules. Patients on self-funded plans should check directly with their benefits administrator rather than assuming standard Ohio commercial formulary terms apply.

The Merck Savings Card for Belsomra

Merck offers a co-pay savings card for commercially insured patients that can reduce out-of-pocket Belsomra costs to as little as $0 for the first prescription fill and $30 per month thereafter, up to a maximum annual benefit.

The card has several restrictions. It does not apply to prescriptions paid by Medicare, Medicaid, TRICARE, or any other federal or state government program. Ohio patients enrolled in a Health Insurance Marketplace plan (Affordable Care Act exchange plan) are eligible only if their plan is not subsidized by the federal government.

To activate the card, patients register on the Merck website or receive a physical card from their prescribing provider. The savings are applied at the pharmacy point of sale and reduce the patient's cost-share after insurance adjudication. The card cannot reduce the price below the pharmacy's contracted rate with the insurer.

For uninsured Ohio patients paying cash, the Merck savings card does not apply. Cash-pay patients should instead explore manufacturer patient assistance or compounded alternatives.

Compounded Suvorexant in Ohio

Compounded suvorexant is available through licensed 503A pharmacies in Ohio. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound medications based on individual patient prescriptions from a licensed prescriber.

Ohio's 503A compounding rules are governed by the Ohio Board of Pharmacy, which requires compounding pharmacies to meet USP 795 (non-sterile) or USP 797 (sterile) standards. Suvorexant, as an oral tablet alternative, falls under non-sterile compounding.

There are practical considerations. Not every Ohio compounding pharmacy stocks suvorexant active pharmaceutical ingredient (API). Patients should call ahead to confirm availability. The compounded product may differ from the brand-name tablet in excipients, dissolution profile, and bioavailability. No compounded version has undergone the bioequivalence testing required for FDA-approved generic drugs.

According to FDA guidance on compounding, compounded drugs are not FDA-approved and should be used only when a commercially available product does not meet a patient's medical needs (for example, a patient who cannot swallow tablets and needs a liquid formulation). Prescribers in Ohio should document the clinical rationale for choosing a compounded product.

Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center, has stated: "Orexin receptor antagonists represent a mechanistically distinct approach to insomnia treatment, targeting the wake-promoting system rather than broadly sedating the brain." This distinction matters when clinicians evaluate whether a DORA like suvorexant is appropriate for a given patient, regardless of formulation source.

Telehealth Prescribing of Belsomra in Ohio

Ohio permits telehealth prescribing of suvorexant. The Ohio State Medical Board allows physicians and advanced practice providers to prescribe Schedule IV controlled substances via telemedicine after conducting an appropriate evaluation, which can include a synchronous audio-video visit.

This means Ohio residents can obtain a Belsomra prescription without an in-person office visit. Several national telehealth platforms operating in Ohio, including those specializing in sleep medicine, can prescribe suvorexant after a virtual consultation and medical history review.

There are two requirements to keep in mind. First, the prescriber must hold an active Ohio medical license (or be practicing under a valid interstate compact agreement). Second, Ohio's controlled substance prescribing rules require that the telehealth encounter include real-time, two-way audio and video. Asynchronous (store-and-forward) encounters alone are not sufficient for Schedule IV prescriptions.

The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid prescription based on at least one in-person or DEA-qualifying telemedicine encounter. The DEA's 2025 telemedicine rule extends pandemic-era flexibilities, allowing initial prescriptions via telehealth for Schedule III through V substances without a prior in-person visit.

How Belsomra Compares to Other Ohio Sleep Medication Costs

Placing Belsomra's Ohio pricing in context helps patients and prescribers weigh cost against mechanism and side-effect profile. Generic zolpidem (immediate-release) costs approximately $5 to $15 per month at Ohio pharmacies. Generic eszopiclone runs $10 to $25 per month. Generic trazodone, used off-label for insomnia, costs under $10 per month.

The newer DORA-class alternative, lemborexant (Dayvigo), carries a similar list price to Belsomra (approximately $350 per month) and faces comparable insurance hurdles. In a head-to-head polysomnographic study, Murphy et al. (2020; N=1,006) found that lemborexant 10 mg produced statistically greater improvements in sleep onset latency and wake after sleep onset compared to zolpidem ER 6.25 mg at one month, though both DORAs and Z-drugs are recommended options in the AASM guideline.

The cost gap between generic sedative-hypnotics and brand-name DORAs explains why most Ohio insurers require step therapy. Patients who have tried and failed (or who have documented contraindications to) at least one generic option are more likely to receive coverage approval for suvorexant.

A 2022 analysis in the Journal of Clinical Sleep Medicine estimated that 40% of insomnia patients on initial zolpidem therapy discontinue within 12 months due to side effects or insufficient efficacy. For this population, the added cost of a DORA may be justified on a per-quality-adjusted-life-year basis.

Practical Steps to Minimize Belsomra Cost in Ohio

Patients filling Belsomra in Ohio should follow a specific sequence to find the lowest price.

Start by confirming your insurance formulary tier and prior authorization requirements. If Belsomra is covered, calculate your expected copay and compare it against the cash price with a discount card. The Merck savings card may reduce your copay to $30 or less if you carry commercial insurance.

If you are uninsured or underinsured, check eligibility for the Merck Patient Assistance Program. Qualifying patients receive Belsomra at no cost. If your income exceeds the program threshold, compare cash prices across Ohio pharmacies using discount card platforms. The $85 average is a benchmark, but individual pharmacy pricing may fall below $70 in some Ohio markets.

For patients open to compounding, contact a licensed Ohio 503A pharmacy to request a suvorexant price quote. Compounded pricing can be lower, but confirm with your prescriber that a compounded product is appropriate for your clinical situation.

The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before pharmacotherapy for chronic insomnia (Edinger et al., 2021). CBT-I is covered by most Ohio insurance plans and may reduce or eliminate the need for long-term medication costs.

Suvorexant's standard dosing is 10 mg taken within 30 minutes of bedtime, with an option to increase to 20 mg if 10 mg is tolerated but insufficiently effective. The FDA label recommends against doses exceeding 20 mg due to next-day somnolence risk. Patients should not take Belsomra with or within two hours of a meal, as food delays onset by approximately 1.5 hours.